Galenica Reports Solid Sales Growth in Early 2025

The Galenica Group reported a 4.7% increase in sales, reaching CHF 1,314.2 million in the first four months of 2025. This performance surpasses the overall pharmaceutical market growth of 4.3%. Key drivers included strong demand for GLP-1-based medications and a widespread flu outbreak that boosted prescription drug sales.

The Products & Care segment saw a 5.3% increase, with local pharmacies growing by 4.8%. The Logistics & IT segment achieved a 4.8% rise, with Wholesale contributing notably.

Galenica maintains its forecast for 2025, projecting sales growth of 3-5% and EBIT growth of 4-6%. The company's retail business, including local pharmacies and online shops, expanded, though Pharmacies at Home saw a slight decline.

Verfora strengthened its market position with a 14.5% rise in sales, bolstered by Cooper Consumer Health products. Logistics & IT Services achieved growth driven by internal IT enhancements.